chrisvoncsefalvay/vaers-outcomes huggingface dataset:
dizziness/dizzy/almost felt like fainting; felt like fainting; racing heart; sweating; This is a spontaneous report from contactable consumers (one is the patient). A 37-year-old male patient received bnt162b2 (BNT162B2), dose 1 via an unspecified route of administration in the left arm on 19Feb2021 13:00 [also reported as 26Feb2021 12:45 PM] (Lot Number: EL9267; Expiration Date: May2021) as a single dose for covid-19 immunisation. Medical history included drug penicillin allergies and low testosterone ongoing since 2018. Concomitant medication included testosterone cipionate (TESTOSTERONE CYPIONATE) for low testosterone, start and stop date were not reported. The patient previously took amoxicillin but had allergies. The patient reported that a few minutes after his first vaccination (19Feb2021), he experienced a racing heart, dizziness, sweating, and almost felt like fainting. A couple waves of this hit him and subsided after 10-15 minutes. The events required emergency room visit. The patient has not been covid tested post vaccination. The patient was not diagnosed with covid prior vaccination. The patient has his blood checked twice/year all normal levels (unspecified date). The patient mentioned that he became slightly dizzy after receiving his first COVID-19 vaccine and he was not nervous or scared prior to or following receiving the vaccine. He also does not have history or problems receiving other vaccines or blood draws when he received the second vaccine, he felt normal for a couple minutes although he would feel "something" thought his body immediately after the injection. A few minutes went suddenly, he became very dizzy or short of breath, EMS was on standby at this site, so they advised him to sit on the floor. They connected heart /02 monitor to him (2021), and his heart rate was very highly (around 130 BPM) or then it would swing widely to less than 50 BPM. During these swings, he would get very dizzy or faint. This happened multiple times starting from less severe to severe with fainting, to finally going away, unfortunately after 30 minutes or so when the heart rate swings were observed, EMS administered Epinephrine and Benadryl in IV form. He was taken to a hospital via ambulance where he was later discharged after no issue in observation. The events tachycardia, dizziness and fainting were considered serious with seriousness criterion of hospitalization/prolongation of hospitalization and important medical event. The outcome of the events was recovering.
Redness, injection site swelling, hot to touch, spread around arm radius. Lasted for four days. Treated with Ice, BENADRYL, and Ibuprofen.
Moderna COVID-19 Vaccine EUA  * Significant blind spot in center of field of vision *Difficulty focusing vision * Significant dizziness (likely due to blind spot)
Injection site was high on deltoid less one inch from shoulder joint.  Within 2 hours, swelling occurred from shoulder along clavicle to neck, with moderate to severe pain.  Patient had ongoing pain, eventually returned to primary provider.  The provider denied vaccination could cause the symptoms, prescribed tramadol and meloxicam, ordered xray and physical therapy.  (See below.)  Condition did not improve after 3 months.  On followup, provider admitted the symptoms are consistent with SIRVA, consulted specialist.  Per provider, specialist declined to see patient - SIRVA not treatable except with time, NSAIDs, physical therapy.  Physical Therapist concurs that symptoms consistent with SIRVA.  Primary prescribed prednisone 20 mg per day for five days two weeks ago.  Condition improved but did not resolve.
adm to ICU 19AUG93 in shock shortly p/receiving routine Typhoid innoculation @ clinic; systemic reaction to typhoid;
Pt had sob and chest tightness that started hours within  vaccine. On 4/14/2021 O2 sat normal at rest, but desaturate to high 80's with exercise. Symptoms have been improved since onset
pt admitted to hosp from ED with generalized weakness; found to be positive for COVID; O2 supplementation; pt experienced cardiorespiratory arrest; CPR; intubated; transferred ICU; family then made pt DNR; AKI with hyperkalemia; sepsis from multiple infected chronic wounds - pt not stable enough to have surgery on wounds; pt's condition worsened requiring 3 vasopressors; transitioned to comfort care; pt passed away in the hospital
Temp of 101.5, nauseous, fatigue, body aches, dry heaving
Around noon she got really hot, sick to stomach, fainty, hard to talk and a headache.  Call the ambulance and refused transport to the hospital.  Lasted approximately 24 hours.
Patient received 1st dose of pfizer COVID vaccine 06/29/21. After administration, the patient and his family (brother and father) were instructed to wait the required 15 mins after receiving the vaccine. The patients brother and father stepped away to go to the bathroom while the patient stayed in the waiting area. The patient received the vaccine at 7:15p and the incident occurred at ~7:25p. The patient said they felt unwell to one of the techs in the pharmacy and they proceeded to get the pharmacist's attention. The pharmacist approached the patient and proceeded asking questions regarding the patient's symptoms. They patient stated they felt unwell and possibly needed to vomit. The pharmacist grabbed a trash can to give the patient and paged the father back to the pharmacy. The pharmacist stayed by the patient's side until the father returned and she informed him of what was going on. The patient stated this had happened previously when they received a vaccine ~1 year ago so it wasn't a first time occurrence. The pharmacist provided the patient with cold water and ensured they were okay to leave before letting them go after waiting the required 15 minutes. Patient is due back for the second dose on 7/20/21. Special precautions will be taken to ensure the patient is okay before leaving, including waiting 30 minutes due to a previous adverse reaction to the vaccine.
Fever; Chills; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Fever) and CHILLS (Chills) in a 77-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included COVID-19 (Patient was diagnosed with Covid-19 two and a half weeks ago with just mild symptoms.).    On 11-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Feb-2021, the patient experienced PYREXIA (Fever) and CHILLS (Chills). At the time of the report, PYREXIA (Fever) had not resolved and CHILLS (Chills) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported. No treatment information was provided.
pt recvd flu vax 5OCT93 & 6 days later devel a lt sided h/a; MD dx idiopathic viral neuropathy;
p/vax rt arm got red, swollen & felt very hot to touch;pt t100-pt took ASA & applied ice to arm;did not call MD lasted about 2 days;
A nurse reported that an 11 month old female received an injection of Typhoid Vaccine, USP, Heat Phenol, Inactivated on 2/8/99. That evening, the infant was cranky and developed a low-grade fever. The next day, she developed a fever of 103F, poor appetite, lethargy and "significant fussiness". She recovered after 2 or 3 days.
By 17:00: redness, hot lump and skin starting, sore.  At bedtime, sore, hot and chills.  11/04/2003 @ 08:15am: 90cm diameter welt-red, hot, sore.  No itching, aching no difficulty breathing.  11/06/2003: Welt red but going down.
p/vax pt exp arthralgias, myalgias & h/a, heart palpitations;no cardiac testing was performed;
NO ADVERSE EVENT OCCURRED WITH THIS VACCINE ADMINISTRATION.  The vaccine was not reconstituted properly and therefore we are unsure of the concentration the patient received. We called the patient and she had no adverse event from the vaccine delivery. She stated her arm was sore, but just like when she has received a Tetanus vaccine.
Not Eating; Not drinking; Not Eating; Not drinking; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DECREASED APPETITE (non-serious), OLIGODIPSIA (non-serious), outcome "unknown" and all described as "Not Eating; Not drinking".  Additional information: The reporter wanted to know that how long do the side effects last because her husband had all the side effects, they got the shot Sunday and he is not eating, he is not drinking, what she supposed to do. she can't take him to the hospital. Reporter clarified as her Husband was experiencing from the side effects, no he didn't wanna go to the hospital, we will got all the virus there.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Pounding headache, heart racing to over 145 bps, chest burning and tightness and hard to breath. I was taken to the Emergency Room at Hospital immediately. Reaction occurred within 30 minutes of the injection. An EKG was administered. I was prescribed  prednisone and Benadryl. I was diagnosed with Anaphylaxis.
Patient became upset and started flailing her arms after DTaP vaccination was administered. Unable to safely administer MMR or Varicella vaccines due to patient being upset and inconsolable, vaccines were wasted with another nurse and provider present.
This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a adult female patient who received SHINGRIX. On 21st December 2017, the patient received the 1st dose of SHINGRIX (intramuscular) .5 ml. On 19th January 2018, 29 days after receiving SHINGRIX, the patient experienced injection site pain. On an unknown date, the outcome of the injection site pain was unknown. The reporter considered the injection site pain to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. At 16:52 hours, the patient received SHINGRIX in left arm. When asked if the vaccine was given subcutaneous or intramuscular, the patient said she assumed it was intramuscular because her arm was sore. No information was gathered for the sore arm other than they assumed the shot was given intramuscularly as both he and his wife had sore arms. The case was linked with the case US2018032691, reported for her husband.
HEART PROBLEMS; This spontaneous report received from a consumer via a company representative concerned a male of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, batch number and expiry were not reported) dose, start therapy date were not reported for covid-19 prophylaxis. The batch number was not reported and has been requested. No concomitant medications were reported.  On an unspecified date, the patient experienced heart problems. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from heart problems. This report was non-serious.
My daughter received her recommended 6 month vaccinations on 4/11/2023. The rotavirus vaccine was one of them. The following day she awoke with a high fever of 103 ferinhyte that lasted all day even with taking Motrin every 6 hours. That night her fever increased to 105 ferinhyte and lead to vomiting. Thursday she then had a low fever of 99 and mild diarrhea with vomiting. We were still taking Motrin every 6 hours. Thursday night her fever went back up to 105.8 and we then decided to take her to the emergency room. She had multiple test done and medications to lower her fever, but all test came back negative. The doctor believes it was a side effect due to her vaccinations done that Tuesday, mainly the rotavirus vaccine. Her fever has finally gone down but she still deals with diarrhea and vomiting.
Developed macular papular  rash  on upper left trapezius  about 1 in in diameter with small clear fluid papules and  another spot over the left scapula with  clear fluid papules  over left scapula about 1 in in diameter including area of erythema around lesions at 72 hours post second shot. At 96 hours 4 spots of rash on upper middle chest  and  left lateral upper chest.  Clear fluid oozes  from papules and lesions scab over. Severe itching.  Also tenderness and tightness over left trapezius.
Respiratory failure; Messed up with medication; A spontaneous report was received from a Consumer concerning himself, a 76-year-old, male patient, who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced respiratory failure and messed up with medication/ Medication error.   The patient's medical history was not reported. Concomitant medication was not reported.  On 24 Feb 2021, the patient received their first of two planned doses of mRNA-1273  mRNA-1273 (Lot number: 001A21A) intramuscularly for prophylaxis of COVID-19 infection.  On 24 Feb 2021, after receiving mRNA-1273, the patient experienced respiratory failure and messed up with medication. He was hospitalized in ICU from 27 Feb 2021 till 08 Mar 2021 due to his medication messed up and had a respiratory failure.  Action taken with mRNA-1273 in response to the events was not reported.  The events respiratory failure and messed up with medication were reported considered resolved on 08 Mar 2021.; Reporter's Comments: There is insufficient details to assess the event of medication error as the specific drug and error was not ddescribed as well as the condition leading to error. In addition, limited information has been provide about the event of respiratory failure but for the fact that  it was due to medication error.  Hence assessed as unlikely due to  mRNA-1273
On Thursday following my shot on Monday I began to experience joint pain in my knees and ankles similar to what I had experienced last year after receiving the flu shot.  It has now been 15 days since I received the shot and the joint pain also now includes my toes, feet, hips, back, fingers, wrists, elbows, and shoulders.
pt had adverse rxn to rubella vax; w/in 10 days had swollen glands, fever, joint pain etc; hospitalized 1st time 11 days;
AS soon as received shot, severe pain in my shoulder/arm.  This has not subsided and I received my shot 3 weeks ago.  My shoulder/upper arm is extremely painful, sore, stiff and hurts to move shoulder/arm. I can pinpoint where I was injected.
Information has been received from a healthcare worker referring to an unspecified number of patients of unknown age and gender. On unspecified dates, the patients were vaccinated with an unspecified number of improperly stored doses of RECOMBIVAX HB (lot # L016427, expiration date 03-APR-2017, lot # L018501, expiration date 22-JUN-2017, lot # L025738, expiration date 14-AUG-2017, route not provided). No adverse effects were reported. This is one of several reports received from the same source. Additional information has been requested.
Septic shock with multiple organ failure. Metabolic acidosis ph 6.8, Hyperkalemina 7, D Dimer 35k, INR 10 (liver failure), lactic acid 19 CRRT and bicarb drip for renal failure with the addition of pressors. 5 weeks post COVID-19 diagnosis
Information has been received from a nurse concerning a patient with a history of pneumococcal 23v polysaccharide vaccination and unknown allergies who on approximately 26-OCT-2005 ("within the last week") was vaccinated with a second dose of pneumococcal 23v polysaccharide vaccine (lot unknown).  Subsequently, on an unknown date in 2005, the patient developed redness and swelling at the injection site.  The patient sought unspecified medical attention.  It was unknown if the patient recovered.  There was no product quality complaint involved.
High fever (over 102.9), chills, urinary incontinence with blood in urine. This was from Friday evening (12/28) until Tuesday morning (1/1/13) when his fever was gone. Wednesday (1/2/13) a small red bump rash appeared on his chest and stomach. The Pediatrician suggested it was a virus, but I am positive it was a vaccine reaction. He had no other symptoms of viral infection and his brother and sister have remained healthy.
pt recv vax 16JUN98 & w/in several hr pain worsened & swelling devel @ the inj site;pt was seen by MD 2 days post vax;@ that time the swelling had extended from shoulder to elbow & the area was red;the swollen arm 1.5 x larger than other
received only the liquid component of menveo; received only the liquid component of menveo; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a adolescent male patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA791A, expiry date 31-JAN-2024) for prophylaxis.   On an unknown date, the patient received Menveo. On an unknown date, an unknown time after receiving Menveo, the patient experienced inappropriate preparation of medication (Verbatim: received only the liquid component of menveo) and inappropriate dose of vaccine administered (Verbatim: received only the liquid component of menveo). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown.   Additional Information: Receipt date: 1-Aug-2023 The reporter consented to follow-up. The patient received only the liquid component of Menveo, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered.
nausea, vomiting,  migraine, fever (101.2 degrees), treated with advil/tylenol
Positive for covid post vaccination status and interested in evusheld.; Positive for covid post vaccination status and interested in evusheld; This is a spontaneous report received from a contactable reporter(s) (Nurse) from medical information team.  A patient (no qualifiers provided) received COVID-19 Vaccine - Manufacturer Unknown, as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), outcome "unknown", described as "Positive for covid post vaccination status and interested in evusheld."; COVID-19 (medically significant), outcome "unknown", described as "Positive for covid post vaccination status and interested in evusheld". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: Positive for covid. Clinical course was reported as, Patients at risk for vaccine break through. Positive for covid post vaccination status and interested in evusheld. Reporter stated, Patient will receive the paxlovid protocol. And asks is there any guide as to how long to wait for additional vaccines post paxlovid therapy.  The information on the batch/lot number for COVID-19 Vaccine - Manufacturer Unknown has been requested and will be submitted if and when received.; Sender's Comments: Based on the information provided, known drug safety profile and plausible temporal association, the causality between BNT162B2 and the events Covid 19 and Drug ineffective cannot be completely excluded.
incapacitated; a little reaction; fatigue; chills; headache; This spontaneous case was reported by a consumer and describes the occurrence of ASTHENIA, VACCINATION COMPLICATION, FATIGUE, CHILLS, and HEADACHE in a 48-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 19-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-May-2021, the patient experienced ASTHENIA, VACCINATION COMPLICATION, FATIGUE, CHILLS, and HEADACHE. At the time of the report, ASTHENIA outcome was unknown and VACCINATION COMPLICATION, FATIGUE, CHILLS, and HEADACHE had resolved.            No concomitant and treatment information were reported by the reporter    This case was linked to MOD-2021-402915, MOD-2021-403232 (Patient Link).
Inappropriate schedule of vaccine; headache; shivering; flu like symptoms; injection site bruise; This case was reported by a consumer via call center representative and described the occurrence of headache in a 61-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On 11th October 2018, the patient received the 1st dose of Shingrix (intramuscular). On an unknown date, the patient received the 2nd dose of Shingrix. On 11th October 2018, less than a day after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced headache, shivering, influenza-like symptoms and injection site bruising. On an unknown date, the patient experienced drug dose administration interval too long. On an unknown date, the outcome of the headache, shivering, influenza-like symptoms and injection site bruising were recovered/resolved and the outcome of the drug dose administration interval too long was unknown.   It was unknown if the reporter considered the headache, shivering, influenza-like symptoms and injection site bruising to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient was going to get her 2nd dose next week, which was more than 6 months after the first dose, which led to lengthening of vaccination schedule. The evening of the first dose she started experiencing headache, shivers and flulike symptoms that continued into the next day before resolving. The patient also had a bruise at the injection site that took almost 2 weeks to resolve. The reporter consented to follow up. This case has been linked to US2019GSK080240, same reporter and same patient.
This case was reported by a nurse and described the occurrence of a possible allergic reaction in a 5 year old male pt who received DTAP (Infanrix) for prophylaxis. On an unspecified date, the pt received the 5th dose of Infanrix (Lot # DTPA586B9).  On 03/24/03, at an unspecified time post-immunization, the pt experienced a possible allergic reaction characterized by swelling and redness at the injection site. The event resolved on 03/28/03.  The reporting nurse considered the event was related to vaccination with Infanrix.
Rash, fever, & irritability 48 hrs p/recvd vax; devel aseptic meningitis, hospitalized x 3 days;
she couldn't swallow the pill; swelling; dizziness; allergic reaction; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team, Program ID. The reporter is the patient.  A 78-year-old female patient received rsv vaccine prot.subunit pref 2v (ABRYSVO), on 07Sep2023 as dose number unknown, single (Batch/Lot number: unknown); influenza vaccine live reassort 4v (INFLUENZA VACCINE LIVE REASSORT 4V), on 07Sep2023 as dose number unknown, single (Batch/Lot number: unknown). The patient's relevant medical history was not reported. The patient took concomitant medications. The following information was reported: DYSPHAGIA (non-serious), outcome "unknown", described as "she couldn't swallow the pill"; SWELLING (non-serious), outcome "unknown"; DIZZINESS (non-serious), outcome "unknown"; HYPERSENSITIVITY (non-serious), outcome "unknown", described as "allergic reaction". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of dysphagia, swelling, dizziness, hypersensitivity.  Causality for "she couldn't swallow the pill", "swelling", "dizziness" and "allergic reaction" was determined associated to device constituent of rsv vaccine prot.subunit pref 2v.  Follow-up attempts are completed. No further information is expected.